Doctors Note Logo

Published on: 9/12/2026

Can Zepbound cause pancreatitis or thyroid cancer and what are the warning signs?

Zepbound (tirzepatide) carries a boxed warning for thyroid C-cell tumors, including medullary thyroid carcinoma, seen in rodent studies, and pancreatitis has been reported in people using it, though both risks are considered rare and unconfirmed in humans. Warning signs of pancreatitis include severe, persistent upper abdominal pain that may radiate to the back, often with nausea or vomiting, while possible thyroid tumor signs include a neck lump or swelling, hoarseness, trouble swallowing, or shortness of breath. Your personal risk depends on factors like a family history of medullary thyroid carcinoma, MEN2 syndrome, prior pancreatitis, gallstones, and heavy alcohol use, so there are several important details to consider below before deciding what to do next.

Because these symptoms overlap with far more common and less serious causes, guessing can lead to unnecessary panic or a dangerous delay, and knowing which signs warrant urgent care matters. Take a free, instant, online symptom check to clarify what your symptoms may mean and get guidance on the right next steps.

Last reviewed for medical accuracy: 09/11/2026

answer background

Explanation

Can Zepbound Cause Pancreatitis or Thyroid Cancer? What You Need to Know

Zepbound (tirzepatide) is a prescription injectable medication approved to help manage type 2 diabetes and support weight loss in certain adults. Like all drugs, Zepbound side effects can range from mild to serious. Two of the concerns people often ask about are pancreatitis (inflammation of the pancreas) and thyroid cancer. This guide explains what we know, outlines warning signs, and helps you decide when to seek medical advice.


Understanding Zepbound’s Mechanism

  • Zepbound combines activity at two gut hormone receptors (GIP and GLP-1) to help regulate blood sugar, slow stomach emptying, and reduce appetite.
  • It belongs to a class of drugs similar to GLP-1 receptor agonists (e.g., semaglutide), which have a long track record in diabetes care.
  • Because of its mechanism, Zepbound can affect digestive and endocrine (hormone) systems, leading to certain risks.

Pancreatitis and Zepbound

What Is Pancreatitis?

Pancreatitis means inflammation of the pancreas, an organ behind the stomach that helps digest food and regulate blood sugar. It can be acute (sudden) or chronic (long-term).

Is Pancreatitis a Known Zepbound Side Effect?

  • Class Warning: All GLP-1 receptor agonists carry a warning about possible pancreatitis. While Zepbound is a dual agonist, its safety profile is expected to be similar.
  • Case Reports: Rare cases of pancreatitis have been reported with GLP-1–based therapies. Clinical trials for tirzepatide recorded a low number of events, but they cannot rule out a risk.

Why Might It Happen?

  • Slower stomach emptying and changes in pancreatic enzyme secretion might stress the pancreas.
  • People with a history of pancreatitis or high triglycerides may have higher susceptibility.

Warning Signs of Pancreatitis

Watch for symptoms that require immediate medical attention:

  • Severe, constant pain in the upper abdomen, often radiating to the back
  • Nausea and vomiting that doesn’t go away
  • Tenderness when pressing on your abdomen
  • Rapid heartbeat or fever

If you experience these signs, stop Zepbound (unless your doctor advises otherwise) and seek emergency care.


Thyroid Cancer and Zepbound

Background on Thyroid C-Cell Tumors

Studies in rats found that drugs in the GLP-1 class can cause thyroid C-cell tumors. While rodents are more sensitive, human risk can’t be dismissed entirely.

What the FDA Labels Say

  • Boxed Warning: Zepbound carries a boxed warning about the potential risk of medullary thyroid carcinoma (a rare form of thyroid cancer) based on animal studies.
  • Contraindications: Zepbound should not be used by people with:
    • A personal or family history of medullary thyroid carcinoma (MTC)
    • Multiple endocrine neoplasia syndrome type 2 (MEN 2)

Human Data

  • So far, there is no confirmed increase in thyroid cancer in people on tirzepatide.
  • Ongoing post-marketing studies are monitoring long-term thyroid safety.

Warning Signs of Thyroid Cancer

Early thyroid cancers often cause no symptoms. Still, be alert to:

  • A lump or swelling in the neck, near the thyroid gland
  • Hoarseness or voice changes that do not go away
  • Trouble swallowing or breathing
  • Persistent cough unrelated to a cold
  • Pain in the front of the neck, sometimes radiating to the ears

If you notice any of these, talk to your doctor for evaluation.


Other Common Zepbound Side Effects

While pancreatitis and thyroid concerns are among the more serious, Zepbound can also cause:

  • Nausea, diarrhea, constipation
  • Stomach discomfort, indigestion, burping
  • Decreased appetite and weight loss
  • Injection-site reactions (redness, itching)

Most people find these side effects mild to moderate, often improving over weeks as the body adjusts.


Balancing Benefits and Risks

When considering any medication, weigh potential benefits against possible risks:

  • Benefits of Zepbound

    • Improved blood sugar control
    • Significant weight loss in many users
    • Lower risk of some diabetes-related complications
  • Risks to Keep in Mind

    • Possible digestive side effects (nausea, vomiting)
    • Rare but serious risks like pancreatitis and thyroid C-cell tumors
    • Need for regular monitoring (blood tests, thyroid exams)

Your healthcare provider can help decide if Zepbound is right for you based on your medical history and personal risk factors.


Monitoring and Prevention

To reduce risk and catch complications early:

  • Before Starting Zepbound

    • Tell your doctor about any history of pancreatitis or thyroid issues.
    • Share any family history of thyroid cancer or MEN 2.
    • Get baseline blood tests (pancreatic enzymes, thyroid function).
  • During Treatment

    • Report sudden abdominal pain or persistent nausea right away.
    • Watch for neck lumps, voice changes, or swallowing difficulties.
    • Keep routine follow-up visits for lab checks and physical exams.

What to Do If You Have Symptoms

Not every stomach ache or throat irritation is serious, but it’s best to err on the side of caution:

  1. Track Your Symptoms
    • Note when pain starts, where it hurts, and any other symptoms (vomiting, fever).
  2. Use an Online Symptom Checker
    • For non-emergency concerns, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
  3. Contact Your Healthcare Provider
    • Describe your symptoms in detail and ask if you should stop Zepbound temporarily.
  4. Seek Emergency Care
    • Go to the ER if you have severe abdominal pain, uncontrollable vomiting, high fever, or trouble breathing.

Final Thoughts

Zepbound offers meaningful benefits for blood sugar control and weight management, but like any powerful medication, it carries potential risks. Pancreatitis and thyroid cancer are rare but serious concerns to keep in mind.

  • Stay informed about zepbound side effects.
  • Know the warning signs of pancreatitis and thyroid tumors.
  • Keep up with regular check-ups and lab tests.
  • Use tools like the Ubie Symptom Checker to assess new symptoms.
  • And most importantly, speak to a doctor about anything that could be life threatening or serious.

Your health journey is a partnership. With careful monitoring and open communication, you and your healthcare team can make the safest, most effective choices for your care.

(References)

  • * Mishra R, Raj R, Elshimy G, Zapata I, Kannan L, Majety P, Edem D, Correa R. Adverse Events Related to Tirzepatide. J Endocr Soc. 2023 Feb 9;7(4):bvad016. doi: 10.1210/jendso/bvad016. Epub 2023 Jan 26. PMID: 36789109; PMCID: PMC9915969.

  • * Zeng Q, Xu J, Mu X, Shi Y, Fan H, Li S. Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1214334. doi: 10.3389/fendo.2023.1214334. Epub 2023 Oct 16. PMID: 37908750; PMCID: PMC10613702.

  • * Cai W, Zhang R, Yao Y, Wu Q, Zhang J. Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2024;12:1277113. doi: 10.3389/fpubh.2024.1277113. Epub 2024 Jan 31. PMID: 38356942; PMCID: PMC10864442.

  • * Caruso I, Di Gioia L, Di Molfetta S, Caporusso M, Cignarelli A, Sorice GP, Laviola L, Giorgino F. The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. J Endocrinol Invest. 2024 Nov;47(11):2671-2678. doi: 10.1007/s40618-024-02441-z. Epub 2024 Aug 14. PMID: 39141075; PMCID: PMC11473560.

  • * Ghusn W, Hurtado MD. Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024 Dec;12:100127. doi: 10.1016/j.obpill.2024.100127. Epub 2024 Aug 31. PMID: 39286601; PMCID: PMC11404059.

  • * Guo H, Guo Q, Li Z, Wang Z. Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis. Front Pharmacol. 2024;15:1461398. doi: 10.3389/fphar.2024.1461398. Epub 2024 Nov 13. PMID: 39605914; PMCID: PMC11600108.

  • * Himmerich H. [Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]. Nervenarzt. 2025 May;96(3):247-254. doi: 10.1007/s00115-025-01813-x. Epub 2025 Mar 5. PMID: 40042613; PMCID: PMC12058874.

  • * Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.

  • * Galli M, Benenati S, Laudani C, Simeone B, Sarto G, Ortega-Paz L, Rocco E, Bernardi M, Spadafora L, D'Amario D, Greco E, Frati G, Federici M, Mehran R, Crea F, Angiolillo DJ, Sciarretta S. Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients. J Am Coll Cardiol. 2025 Nov 18;86(20):1805-1819. doi: 10.1016/j.jacc.2025.08.027. Epub 2025 Aug 27. PMID: 40892610.

  • * Ko A, Chang YC, Bahar F, Wang TH, Xanthavanij N, Yu CC, Hsieh RJ, See XY, Lo SW, Song J, Hsia YP, Chiang CH, Xu X, Lin S, Chiang CH. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. Ann Intern Med. 2026 Feb;179(2):216-229. doi: 10.7326/ANNALS-25-02237. Epub 2025 Dec 9. PMID: 41359966.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.